Changes in disease burden can influence mergers and acquisitions (M&A) activity in these sectors. The report found an increase in new patients associated with oncology providers in recent years.
In March, Pfizer announced its intention to acquire cancer therapeutics company Seagen for $43 billion. The acquisition amount exceeds the prices of all of Pfizer’s acquisitions since 2019, according to the report.
